论文部分内容阅读
目的 :观察153 Sm -EDTMP对骨转移癌患者血浆ET、CGRP水平的影响。方法 :5 5例骨转移癌患者 ,按 18 5～ 37MBq/kg的剂量 ,肘静脉注入153 Sm -EDTMP ,放免法测定治疗前后不同时间血浆ET、CGRP的浓度。结果 :血浆ET水平治疗后 1～ 2月较治疗前下降 ,治疗 3月后显著升高 ;CGRP治疗后 1～ 2月较治疗前明显升高 ,3月后降低。结论 :153 Sm -EDTMP可调节ET、CGRP的水平 ,这可能与其治疗骨转移癌的作用密切相关。
Objective: To observe the effect of 153 Sm-EDTMP on plasma ET and CGRP in patients with bone metastases. Methods: Fifty-five patients with bone metastases were treated with 153 Sm-EDTMP in the elbow vein at dose of 18 5 ~ 37 MBq / kg, and plasma concentrations of ET and CGRP were measured by radioimmunoassay before and after treatment. Results: The levels of plasma ET decreased from January to February after treatment, and increased significantly after 3 months of treatment. The levels of plasma ET increased significantly from January to February after treatment and decreased after 3 months. Conclusion: 153 Sm-EDTMP can regulate the levels of ET and CGRP, which may be closely related to its role in the treatment of bone metastases.